CD19 and central nervous system cancer: Neither the percentage of CD19+ B cells, CD3+/CD8+ T cells, CD4+ and CD8+ Tregs nor any of the NK-like T cell subsets differed significantly in patients with gliomas in grade II, III, IV and healthy controls (data not shown).